Cargando…
The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania
Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643143/ https://www.ncbi.nlm.nih.gov/pubmed/28976981 http://dx.doi.org/10.1371/journal.pntd.0005944 |
_version_ | 1783271477681848320 |
---|---|
author | Gass, Katherine M. Sime, Heven Mwingira, Upendo J. Nshala, Andreas Chikawe, Maria Pelletreau, Sonia Barbre, Kira A. Deming, Michael S. Rebollo, Maria P. |
author_facet | Gass, Katherine M. Sime, Heven Mwingira, Upendo J. Nshala, Andreas Chikawe, Maria Pelletreau, Sonia Barbre, Kira A. Deming, Michael S. Rebollo, Maria P. |
author_sort | Gass, Katherine M. |
collection | PubMed |
description | Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more confirmed positive tests in either site is interpreted as an indicator of potential transmission, prompting MDA at the district-level. While this mapping strategy has worked well in high-prevalence settings, imperfect diagnostics and the transmission potential of a single positive adult have raised concerns about the strategy’s use in low-prevalence settings. In response to these limitations, a statistically rigorous confirmatory mapping strategy was designed as a complement to the current strategy when LF endemicity is uncertain. Under the new strategy, schools are selected by either systematic or cluster sampling, depending on population size, and within each selected school, children 9–14 years are sampled systematically. All selected children are tested and the number of positive results is compared against a critical value to determine, with known probabilities of error, whether the average prevalence of LF infection is likely below a threshold of 2%. This confirmatory mapping strategy was applied to 45 districts in Ethiopia and 10 in Tanzania, where initial mapping results were considered uncertain. In 42 Ethiopian districts, and all 10 of the Tanzanian districts, the number of antigenemic children was below the critical cutoff, suggesting that these districts do not require MDA. Only three Ethiopian districts exceeded the critical cutoff of positive results. Whereas the current World Health Organization guidelines would have recommended MDA in all 55 districts, the present results suggest that only three of these districts requires MDA. By avoiding unnecessary MDA in 52 districts, the confirmatory mapping strategy is estimated to have saved a total of $9,293,219. |
format | Online Article Text |
id | pubmed-5643143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56431432017-10-30 The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania Gass, Katherine M. Sime, Heven Mwingira, Upendo J. Nshala, Andreas Chikawe, Maria Pelletreau, Sonia Barbre, Kira A. Deming, Michael S. Rebollo, Maria P. PLoS Negl Trop Dis Research Article Endemicity mapping is required to determining whether a district requires mass drug administration (MDA). Current guidelines for mapping LF require that two sites be selected per district and within each site a convenience sample of 100 adults be tested for antigenemia or microfilaremia. One or more confirmed positive tests in either site is interpreted as an indicator of potential transmission, prompting MDA at the district-level. While this mapping strategy has worked well in high-prevalence settings, imperfect diagnostics and the transmission potential of a single positive adult have raised concerns about the strategy’s use in low-prevalence settings. In response to these limitations, a statistically rigorous confirmatory mapping strategy was designed as a complement to the current strategy when LF endemicity is uncertain. Under the new strategy, schools are selected by either systematic or cluster sampling, depending on population size, and within each selected school, children 9–14 years are sampled systematically. All selected children are tested and the number of positive results is compared against a critical value to determine, with known probabilities of error, whether the average prevalence of LF infection is likely below a threshold of 2%. This confirmatory mapping strategy was applied to 45 districts in Ethiopia and 10 in Tanzania, where initial mapping results were considered uncertain. In 42 Ethiopian districts, and all 10 of the Tanzanian districts, the number of antigenemic children was below the critical cutoff, suggesting that these districts do not require MDA. Only three Ethiopian districts exceeded the critical cutoff of positive results. Whereas the current World Health Organization guidelines would have recommended MDA in all 55 districts, the present results suggest that only three of these districts requires MDA. By avoiding unnecessary MDA in 52 districts, the confirmatory mapping strategy is estimated to have saved a total of $9,293,219. Public Library of Science 2017-10-04 /pmc/articles/PMC5643143/ /pubmed/28976981 http://dx.doi.org/10.1371/journal.pntd.0005944 Text en © 2017 Gass et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gass, Katherine M. Sime, Heven Mwingira, Upendo J. Nshala, Andreas Chikawe, Maria Pelletreau, Sonia Barbre, Kira A. Deming, Michael S. Rebollo, Maria P. The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title | The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title_full | The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title_fullStr | The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title_full_unstemmed | The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title_short | The rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: Examples from Ethiopia and Tanzania |
title_sort | rationale and cost-effectiveness of a confirmatory mapping tool for lymphatic filariasis: examples from ethiopia and tanzania |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643143/ https://www.ncbi.nlm.nih.gov/pubmed/28976981 http://dx.doi.org/10.1371/journal.pntd.0005944 |
work_keys_str_mv | AT gasskatherinem therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT simeheven therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT mwingiraupendoj therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT nshalaandreas therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT chikawemaria therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT pelletreausonia therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT barbrekiraa therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT demingmichaels therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT rebollomariap therationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT gasskatherinem rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT simeheven rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT mwingiraupendoj rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT nshalaandreas rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT chikawemaria rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT pelletreausonia rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT barbrekiraa rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT demingmichaels rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania AT rebollomariap rationaleandcosteffectivenessofaconfirmatorymappingtoolforlymphaticfilariasisexamplesfromethiopiaandtanzania |